At a glance
- Originator Bristol-Myers Squibb
- Class Anti-ischaemics; Antihypertensives; Pyrimidines
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension; Ischaemic heart disorders
Most Recent Events
- 01 Sep 1998 No-Development-Reported for Ischaemic heart disorders in USA (Unknown route)
- 15 Sep 1995 Preclinical development for Ischaemic heart disorders in USA (Unknown route)
- 14 Sep 1995 Discontinued-Preclinical for Hypertension in USA (Unknown route)